Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00225277 · ClinicalTrials.gov registry record · Phase 3

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
547
Enrollment target
20
Study locations

NCT00225277 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 547 participants, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00225277, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
547 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.

Conditions Studied

Diabetes Mellitus

Interventions

  • DRUG Pioglitazone
  • DRUG Glimepiride

Study Locations (20)

California

  • - Huntington Beach
  • - Los Angeles
  • - Sacramento
  • - San Diego
  • - Torrance

Kentucky

  • - Edgewood
  • - Lexington
  • - Louisville

Connecticut

  • - Bridgeport
  • - Farmington

Florida

  • - Bay Pines
  • - Jacksonville

Alabama

  • - Birmingham

Arizona

  • - Phoenix

District of Columbia

  • - Washington D.C.

Georgia

  • - Decatur

Trial Details

FieldValue
Enrollment Target 547 participants
Start Date 2003-07
Est. Completion 2007-10
Phase Phase 3

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00225277

The ClinicalTrials.gov registry entry for NCT00225277 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (71% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Pioglitazone is the first listed.

NCT00225277 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Kentucky, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00225277 about?

NCT00225277 is a clinical study titled "Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus". The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.

What is the current status of trial NCT00225277?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2003-07. Estimated completion is 2007-10.

What conditions does trial NCT00225277 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00225277?

The interventions under investigation include: Pioglitazone (DRUG), Glimepiride (DRUG).

Who is sponsoring clinical trial NCT00225277?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00225277 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.